PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostBlog Post
Interview with John Moore
Meet John Moore, the proposed new board member for PHI. John’s extensive experience and visionary mindset make him an invaluable addition to our team. Let’s dive into his journey and what made him interested in PHI.
PostNews: Press Release
Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 19 August 2024
Phase Holographic Imaging PHI AB (publ), reg. no. 556542-7811 (the “Company”), will hold an extraordinary general meeting on 19 August at 14:00 at the Company’s premises at Skiffervägen 48 in Lund.
PostNews: Press Release
Board member Leland Foster resigns due to personal reasons
PHI announces the resignation of esteemed board member Leland Foster. Mr. Foster has decided to resign from his position due to his age and his desire to retire from professional commitments. After this, the Board of Directors continues to have a quorum in accordance with the Articles of Association.
PostNews
BioStock: PHI aims for US listing
BioStock has talked to PHI’s CEO, Patrik Eschricht, to learn more about what the dual listing on the US OTCQB market means for the company and its plans for the future.
PostNews: Press Release
PHI applies for listing on OTCQB in the United States
PHI is pursuing a dual listing on the US-based OTCQB Venture Market to provide US-based investors with the ability to invest in PHI. PHI aims to solidify further its presence in the major US market and within regenerative medicine, a rapidly evolving field, spearheaded by the United States globally. The application process has been initiated, and PHI expects to receive approval in the third quarter of 2024.
PostNews: Interim Report
Interim Report 4 2023/24
This spring has been a dynamic and productive period for PHI, as our team and partners have made significant efforts on multiple fronts. Externally, our collaboration with Altium has focused on expanding our sales processes and networks and enhancing our market presence. Internally, our dedicated team has been advancing our ongoing regenerative medicine projects and refining our HoloMonitor technology.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
New CEO commentary: “Bridging Corona”
As the dust from the stampede of bewildered politicians and overconfident billionaires settles, we begin to discern the new world shaped by the COVID-19 pandemic.
New CEO commentary: “Joining forces with Huntsman”
PHI recently joined forces with the Huntsman Cancer Institute in the battle against cancer.
CEO interview in BioStock
In the article published today by BioStock, the company’s CEO Peter Egelberg comments on the developments during the past autumn.
New CEO commentary: “The Single-Cell Revolution”
PHI’s CEO and founder Peter Egelberg comments the recently published innovation report from the UN agency World Intellectual Property Organization.
